ArticleThe Lancet regional health. Europe2023
Severity of Omicron (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: A prospective cohort study in Bristol, United Kingdom.
Article in The Lancet regional health. Europe, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 2 syntheses or guidelines pooled it, 171 citations in OpenAlex.
- Prophylactic-dose direct oral anticoagulants for non-hospitalised people with COVID-19: A meta-analysis of randomised controlled trials.Journal of global health · 2024Pooled it
- Comparison of Omicron and Delta Variants of SARS-CoV-2: A Systematic Review of Current Evidence.Infectious disorders drug targets · 2024Pooled it
- Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial.JAMA network open · 2024Trial
- Article
- Gut Microbiota Predicts the Risk of Future COVID-19 Hospitalization and Mortality: Insights From the Population-Based HELIUS Study.The Journal of infectious diseases · 2026Article
- Article
- SARS-CoV-2 infection in lung transplant recipients: a single-center retrospective study in Japan.Surgery today · 2026Article
- Time-Dependent Outcomes of Convalescent Plasma in Early COVID-19: A Single-Center Cohort with a Host-Pathogen Perspective.Pathogens (Basel, Switzerland) · 2025Article
- Role of vaccines in competitive displacement between SARS-CoV-2 viruses as revealed by the modeling of surveillance data.Infection · 2025Article
- SARS-CoV-2 Infection With Alpha B.1.1.7 Virus Induced Higher Antibody Responses Than Earlier Non-VOC Variants During the First Waves of the COVID-19 Pandemic in Norway.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2025Article
- Implementation of the multicountry WHO COVID-19 pregnancy cohort study: challenges and lessons learned during the pandemic.Reproductive health · 2025Article
- Deep Learning-Based Automatic Segmentation and Analysis of Mitochondrial Damage by Zika Virus and SARS-CoV-2.Viruses · 2025Article
- Differences in the Clinical Course of COVID-19 in Patients Hospitalized in the 2023/2024 and 2024/2025 Seasons.Journal of clinical medicine · 2025Article
- COVID-19 Clinical Predictors in Patients Treated via a Telemedicine Platform in 2022.Tropical medicine and infectious disease · 2025Article
- Mouse Adapted Omicron BA.5 Induces A Fibrotic Lung Disease Phenotype in BALB/c Mice.bioRxiv : the preprint server for biology · 2025Article
- Coronavirus Disease 2019 Vaccination Booster Effectiveness Based on the 2022 Japanese Dialysis Registry.Nephrology (Carlton, Vic.) · 2025Article
- SARS-CoV-2 spike protein: structure, viral entry and variants.Nature reviews. Microbiology · 2025Review
- Severe COVID-19-related Pneumonia Seven Years after Heart Transplantation.Internal medicine (Tokyo, Japan) · 2025Article
- The clinical impact of prolonged steroid therapy in severe COVID-19 patients: a retrospective cohort study with propensity score matching.BMC pulmonary medicine · 2025Article
- Determinants of SARS-CoV-2 outcomes in patients with cancer vs controls without cancer: a multivariable meta-analysis with genomic imputation.EClinicalMedicine · 2025Article
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 4 institutions in 2 countries.
Funding
Abstract
Background: There is an urgent public health need to evaluate disease severity in adults hospitalised with Delta and Omicron SARS-CoV-2 variant infections. However, limited data exist assessing severity of disease in adults hospitalised with Omicron SARS-CoV-2 infections, and to what extent patient-factors, including vaccination, age, frailty and pre-existing disease, affect variant-dependent disease severity. Methods: A prospective cohort study of adults (≥18 years of age) hospitalised with acute lower respiratory tract disease at acute care hospitals in Bristol, UK conducted over 10-months. Delta or Omicron SARS-CoV-2 infection was defined by positive SARS-CoV-2 PCR and variant identification or inferred by dominant circulating variant. We constructed adjusted regression analyses to assess disease severity using three different measures: FiO Findings: Independent of other variables, including vaccination, Omicron variant infection in hospitalised adults was associated with lower severity than Delta. Risk reductions were 58%, 67%, and 16% for supplementary oxygen with >28% FiO Interpretation: We provide reassuring evidence that Omicron infection results in less serious adverse outcomes than Delta in hospitalised patients. Despite lower severity relative to Delta, Omicron infection still resulted in substantial patient and public health burden and an increased admission rate of older patients with Omicron which counteracts some of the benefit arising from less severe disease. Funding: AvonCAP is an investigator-led project funded under a collaborative agreement by Pfizer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.